Tohoku J. Exp. Med., 2021 August, 254(4)

Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020

Jiaming Qu,1 Yanming Ding,2 Kaiwen Jiang,1 Junxia Hao,1 Yuanzhi Li,2 Aijun Zhang,1 Zhaohang Li,1 Guanpeng Qi,1 Ze Xu,1 Xin Liu,1 Juman Ma,1 Kaishun Bi1 and Zuojing Li3

1School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
2School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Liaoning, Shenyang, China
3School of Medical Devices, Shenyang Pharmaceutical University, Shenyang, Liaoning, China

Nephrotoxicity occasionally occurs during treatment with immune checkpoint inhibitors (ICIs). Few related studies compare the differences between these drugs. This study aimed to systematically characterize nephrotoxicity after ICI initiation. Data were extracted from the US FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis, including information components (ICs) and reporting odds ratios (RORs), was performed to determine the potential renal toxicity of ICIs. A total of 7,204 reports of renal adverse events (AEs) were identified in the FAERS database. Renal AEs were most commonly reported for nivolumab (46.84%). Strong signals were detected in male patients combined with ICIs. In the clinical application of ICIs, attention should be paid to patients, especially male patients, with acute kidney injury, nephritis, autoimmune nephritis and other nephrotoxic AEs. The use of ICIs is likely to aggravate their condition.

Key words —— adverse events; Adverse Event Reporting System; disproportionality analysis; immune checkpoint inhibitors; nephrotoxicity


Tohoku J. Exp. Med., 2021, 254, 275-282

Correspondence: Zuojing Li, School of Medical Devices, Shenyang Pharmaceutical University, No.103 Wenhua Street, Shenyang, Liaoning Province 110016, China.